Our previous studies demonstrated that TRIM31 and TRIM37 confer gemcitabine and fluorouracil resistance in PC by activating the NF-κB and AKT–GSK-3β–β-catenin signaling pathways, respectively [13, 14]. This evidence concerns the gene AKT1 and pachyonychia congenita.